Related Experiment Video
Updated: Mar 28, 2026
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
Published on: January 12, 2017
Testis expressed 19 is a novel cancer-testis antigen expressed in bladder cancer
Jianhua Zhong1,2, Yan Chen1,3, Xinhui Liao4
1National-Regional Key Technology Engineering Laboratory for Clinical Application of Cancer Genomics, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, 518037, China.
Abstract:
Bladder cancer exhibits high mortality as a result of limited therapeutic options and a high recurrence rate. Accordingly, novel treatments such as immunotherapy have emerged as promising therapeutic modalities to prolong overall patient survival and effect a disease cure, which has renewed enthusiasm for the identification of tumor-specific target antigens. Cancer-testis (CT) antigens are recognized as ideal targets for immunotherapy because of their expression features and high immunogenicity profiles. Here, we investigate the expression pattern of a novel CT antigen, testis-expressed 19 (TEX19), in patients with bladder carcinoma and among multiple human tissues. Six bladder cancer cell lines (T24, UM-UC-3, J82, 5637, SW780, and RT4) were also analyzed for TEX19 expression. Our results reveal that TEX19 expression in normal tissue is restricted to human testis. In addition, TEX19 mRNA expression was detected in 60 % (24/40) bladder cancer samples, whereas 58.20 % (110/189) were positive for TEXT19 protein expression. Compared to low-grade tumors, TEX19 exhibited increased expression in high-grade tumors, from 53.69 to 77.14 %, respectively (P = 0.011). TEX19 was also expressed in all six bladder cancer cell lines. Together, our findings suggest that TEX19 represents a novel CT gene and might play a role in the progression of bladder cancer and that this gene therefore provides a potential target for immunotherapy treatment strategies against bladder cancer.
Insights
Testis-expressed 19 (TEX19) is a novel cancer-testis antigen found in bladder cancer tissues and cell lines. TEX19 shows increased expression in high-grade tumors, suggesting its potential as a target for immunotherapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Bladder cancer has high mortality due to limited treatments and recurrence.
- Immunotherapy offers promising new treatment strategies for bladder cancer.
- Tumor-specific target antigens are crucial for effective immunotherapy.
Purpose of the Study:
- To investigate the expression pattern of the novel cancer-testis antigen, testis-expressed 19 (TEX19).
- To evaluate TEX19 as a potential immunotherapy target in bladder cancer.
Main Methods:
- TEX19 expression was analyzed in normal human tissues and bladder cancer samples (mRNA and protein).
- TEX19 expression was assessed in six human bladder cancer cell lines.
- Correlation between TEX19 expression and tumor grade was examined.
Main Results:
- TEX19 expression was restricted to normal human testis.
- TEX19 mRNA was detected in 60% of bladder cancer samples, and protein in 58.2%.
- TEX19 expression was significantly higher in high-grade (77.14%) versus low-grade (53.69%) bladder tumors and present in all tested cell lines.
Conclusions:
- TEX19 is a novel cancer-testis gene expressed in bladder cancer.
- TEX19 expression correlates with higher tumor grade, indicating a role in bladder cancer progression.
- TEX19 represents a potential novel target for bladder cancer immunotherapy.
Related Concept Videos
01:20Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
02:39lncRNA - Long Non-coding RNAs